Showing results (501-510 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|December 20, 2024
Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in NorwayT E Detlie, L N Karlsen, E Jørgensen, et al.Journal of Medical Economics|December 13, 2024
Real-world healthcare resource utilization of Alzheimer's disease in the early and advanced stages: a retrospective cohort studyElnara Fazio-Eynullayeva, Marianne Cunnington, Paul Mystkowski, et al.Journal of Medical Economics|January 2, 2025
Cost-utility analysis of empagliflozin for heart failure in the PhilippinesPrecious Juzenda Montilla, Camilo Oliver Aquino, Elaine Cunanan, et al.Journal of Medical Economics|December 6, 2024
Cost-utility analysis of newborn screening for spinal muscular atrophy in JapanAkira Hata, Akihito Uda, Satoru Tanaka, et al.Journal of Medical Economics|December 12, 2023
Clinical and economic impact of ventricular assist device infections: a real-world claims analysisAnton Y Peleg, Erika D Feller, Marcus Müller, et al.Journal of Medical Economics|February 12, 2024
Economic burden and secondary complications of influenza-related hospitalization among adults in the US: a retrospective cohort studyTianyan Hu, Amanda C Miles, Taryn Pond, et al.Journal of Medical Economics|February 6, 2024
Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in KuwaitGihan Hamdy Elsisi, Mohamed M Ibrahim Mahmoud, Khaldoon Al-Humood, et al.Journal of Medical Economics|February 8, 2024
A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnessesShawn Davies, Emily Boller, Jordan Chase, et al.Journal of Medical Economics|January 31, 2024
Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UKGrant McCarthy, Kate Young, Matthew Madin-Warburton, et al.Journal of Medical Economics|January 16, 2024
Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden - A pilot study comparing extrapolated and observed life-years gainedJonas Björnerstedt, Hannah Almqvist, Douglas Lundin, et al.Pageof 241